Compare JPMorgan Equity Premium Income ETF (JEPI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.84, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while JPMorgan Equity Premium Income ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPI | REGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $812.27 |
52-Week Low | $55.29 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $57.58, showing minimal daily change. Technical indicators are bullish overall, with strong moving average support but a neutral oscillator reading. Recent news highlights its role in income strategies, though some articles note underperformance versus peers. The ETF's covered-call strategy provides monthly income but may limit capital appreciation.
The outlook is mixed: JEPI offers reliable income with a covered-call approach, appealing for risk-averse investors. However, competition from higher-yielding ETFs and potential tax inefficiencies pose risks. Investors should weigh income stability against growth opportunity costs in a rising market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
